Sulfasalazine for the Treatment of Ankylosing Spondylitis: Relic or Niche Medication?

被引：1
|
作者：
Ward, Michael M. [1 ]
机构：
[1] NIAMSD, NIH, Bethesda, MD 20892 USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 06期
关键词：
PLACEBO;
D O I：
10.1002/art.30225
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1472 / 1474
页数：3
相关论文
共 50 条
  • [41] Characteristics of medication-induced xerostomia and effect of treatment
    Ito, Kayoko
    Izumi, Naoko
    Funayama, Saori
    Nohno, Kaname
    Katsura, Kouji
    Kaneko, Noboru
    Inoue, Makoto
    PLOS ONE, 2023, 18 (01):
  • [42] Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
    Baraliakos, X.
    Davis, J.
    Tsuji, W.
    Braun, J.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S13 - S14
  • [43] Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
    X Baraliakos
    J Davis
    W Tsuji
    J Braun
    Arthritis Research & Therapy, 7
  • [44] Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real-life experience
    Can, Meryem
    Aydin, Sibel Z.
    Nigdelioglu, Adil
    Atagunduz, Pamir
    Direskeneli, Haner
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2012, 15 (06) : 526 - 530
  • [45] Treatment of medication overuse headache - guideline of the EFNS headache panel
    Evers, S.
    Jensen, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (09) : 1115 - 1121
  • [46] Youth at entry to residential treatment: Understanding psychotropic medication use
    Griffith, Annette K.
    Smith, Gail
    Huefner, Jonathan C.
    Epstein, Michael H.
    Thompson, Ronald
    Singh, Nirbhay N.
    Leslie, Laurel. K.
    CHILDREN AND YOUTH SERVICES REVIEW, 2012, 34 (10) : 2028 - 2035
  • [47] Effects and Safety of Allogenic Mesenchymal Stem Cell Intravenous Infusion in Active Ankylosing Spondylitis Patients Who Failed NSAIDs: A 20-Week Clinical Trial
    Wang, Peng
    Li, Yuxi
    Huang, Lin
    Yang, Jiewen
    Yang, Rui
    Deng, Wen
    Liang, Biling
    Dai, Lie
    Meng, Qingqi
    Gao, Liangbin
    Chen, Xiaodong
    Shen, Jun
    Tang, Yong
    Zhang, Xin
    Hou, Jingyi
    Ye, Jichao
    Chen, Keng
    Cai, Zhaopeng
    Wu, Yanfeng
    Shen, Huiyong
    CELL TRANSPLANTATION, 2014, 23 (10) : 1293 - 1303
  • [48] Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial
    Dougados, M
    Gueguen, A
    Nakache, JP
    Velicitat, P
    Veys, EM
    Zeidler, H
    Calin, A
    RHEUMATOLOGY, 1999, 38 (03) : 235 - 244
  • [49] Treatment of withdrawal headache in patients with medication overuse headache: a pilot study
    Cevoli, Sabina
    Giannini, Giulia
    Favoni, Valentina
    Terlizzi, Rossana
    Sancisi, Elisa
    Nicodemo, Marianna
    Zanigni, Stefano
    Reggiani, Maria Letizia Bacchi
    Pierangeli, Giulia
    Cortelli, Pietro
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [50] Conventional disease-modifying antirheumatic drugs therapy may not slow spinal radiographic progression in ankylosing spondylitis: results from an 18-year longitudinal dataset
    Lee, Tae-Han
    Koo, Bon San
    Nam, Bora
    Oh, Ji Seon
    Park, Seo Young
    Lee, Seunghun
    Joo, Kyung Bin
    Kim, Tae-Hwan
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2020, 12
12345